Prostate cancer is the cancer of prostate gland which resides under the urinary bladder, and in
anterior of the rectum and its size changes with the growing age. It develops quickly during the
puberty and pumped by the increase in androgens. These hormones include testosterone and
dihydrotestosterone (DHT). There were 50 healthy individuals included as control group and 50
diagnosed prostate cancer patients were taken as subjects. The blood sample was centrifuged
within one hour and serum was separated. MDA, SOD, GSH, GR, CAT, was assessed by
spectrophotometrically. WhereasIL-6, TNF-?, OPG, sRANKL, Osteonectin, Osteopontin,
Osteocalcin and bone Sialoprotein were measured by commercially available ELISA kits.
Malondialdehyde (MDA) play a crucial role in the pathogenesis and progression of prostate
cancer. The level of MDA was significantly (p=0.015) raised in prostate cancer patients
(3.66±0.42 ?mol/L) as compared to healthy control (0.93±0.033 ?mol/L). Enzymatic and nonenzymatic
antioxidants profile specifically include SOD, GSH, CAT and GR reflect destructive
role of ROS in the development of prostate cancer. Decrease level of SOD (0.46±0.061 U/ml Vs.
0.63±0.067 U/ml), GSH (5.16±1.26 ?mol/L Vs. 8.26±3.26 ?mol/L), GR (3.28±0.09 ?mol/L Vs. 6.99±1.08 ?mol/L) and CAT (4.08±1.33 U/L Vs. 6.45±1.88 U/L) were observed in prostate
cancer patients as compared to healthy individuals. The level of proinflammatory cytokines IL-6
and TNF-? differed significantly increased in disease group (15.66±4.19 pg/ml and 31.26±4.16
pg/ml) as compared to controls (6.22±2.08 pg/mland 20.18±3.29 pg/ml). Increased levels of
OPG, sRANKL, osteonectin, osteopontin, osteocalcin and bone sialoprotein were observed in
prostate cancer patients (489.26±16.33 ng/ml, 4.26±1.22 ng/ml, 209.92±4.16 ng/ml, 658.29±4.19
ng/ml, 5.16±4.26 ng/ml and 286.26±6.35 ng/ml) as compared to control individuals
(655.26±15.36 ng/ml, 1.74±0.156 ng/ml, 68.29±6.26 ng/ml, 423.29±12.56 ng/ml, 3.06±6.35
ng/ml and 155.26±3.29 ng/ml). Present study depicts that osteopontin, osteonectin and bone
sialoprotein contribute in the progression of tumor in prostate cancer. Moreover, the expression
of these variables varies between different types of bone metastasis. The expression of these
bone proteins have strongly associated with osteoporotic phenotype in prostate cancer.
Osteopontin, osteonectin and bone sialoprotein are the potential novel biomarkers and anticancer
therapeutic target to manage tumor progression in prostate cancer.
Keywords: Prostatecancer, Malondialdehyde, Interlukins-6, Tumor necrosis factor-?,
osteopontin, osteonectin, bone sialoprotein
https://ijbpas.com/pdf/2019/May/MS_IJBPAS_2019_4724.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2019/8.5.4724
